MIRA
INFORM REPORT
|
Report Date : |
26.04.2012 |
IDENTIFICATION DETAILS
|
Name : |
Shanghai Jinhe
Bio-Technology Co., Ltd. |
|
|
|
|
Registered Office : |
Suite
A-4, |
|
|
|
|
Country : |
China |
|
|
|
|
Date of Incorporation : |
19.03.2002 |
|
|
|
|
Com. Reg. No.: |
310118002047094 |
|
|
|
|
Legal Form : |
Limited Liabilities Company |
|
|
|
|
Line of Business : |
Engaged in researching, developing, manufacturing and selling Anti-cancer
APIs and intermediates |
|
|
|
|
No. of Employees : |
100 |
RATING & COMMENTS
|
MIRA’s Rating : |
B |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively below
average. |
Small |
|
Status : |
Moderate |
|
Payment Behaviour : |
No complaints |
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – September 30, 2011
|
Country Name |
Previous Rating (31.12.2011) |
Current Rating (31.03.2012) |
|
China |
A2 |
A2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
Company name and address
Shanghai Jinhe Bio-Technology Co., Ltd.
Suite A-4, Liantang Industrial Park,
Qingpu District, Shanghai, 201716
China
TEL: 86 (0)
21-59810660/59810601
FAX: 86 (0) 21-59810661
EXECUTIVE SUMMARY
INCORPORATION DATE : MARCH 19, 2002
REGISTRATION NO. : 310118002047094
REGISTERED LEGAL FORM : LIMITED LIABILITIES COMPANY
STAFF STRENGTH : 100
REGISTERED CAPITAL : CNY 3,000,000
BUSINESS LINE : R&D, MANUFACTURe
TURNOVER :
N/A
EQUITIES :
N/A
PAYMENT :
AVERAGE
RECOMM. CREDIT RANGE : small AMOUNT
MARKET CONDITION : AVERAGE
FINANCIAL CONDITION : N/A
OPERATIONAL TREND : STEADY
GENERAL REPUTATION : AVERAGE
EXCHANGE RATE :
CNY
6.3096 = USD 1
Adopted abbreviations
ANS - amount not
stated
NS - not stated
SC - subject
company (the company inquired by you)
NA - not available
CNY - China Yuan Renminbi
SC was registered as a Limited Liabilities Company at local Administration for
Industry & Commerce (AIC - The official body of issuing and renewing
business license) on March 19, 2002.
Company Status: Limited Liabilities Company This form of business in PR
China is defined as a legal person. No more than fifty shareholders
contribute its registered capital jointly. Shareholders bear limited
liability to the extent of shareholding, and the co. is liable for its
debts only to extent of its total assets. The characteristics of this form
of co. are as follows: Upon the establishment of the
co., an investment certificate is issued to the each of shareholders. The board of directors is
comprised of three to thirteen members. The minimum registered capital
for a co. is CNY 30,000. Shareholders may take their
capital contributions in cash or by means of tangible assets or intangible
assets such as industrial property and non-patented technology. Cash contributed by all
shareholders must account for at least 30% of the registered capital. Existing shareholders have
pre-exemption right to purchase shares of the co. offered for sale by the
other shareholders and to subscribe for the newly increased registered
capital of the co.
SC’s registered business scope includes four technical services in the
field of Bio-technology, producing and processing plant purifications of taxane
(excluding special approval), importing and exporting cargo and technology,
selling plant purifications (excluding medicine) and biological materials.
(Business operation that involves administrative permit shall run with the
permit).
Mr. Zhang Weizhong is the legal representative and chairman of SC at present.
SC is
known to have approx. 100 employees at present.
SC is currently operating at the above stated address, and this address houses its operating office and factory in industrial zone of Shanghai. SC’s employee refused to release the detailed information of the premise.
www.biotaxu.com The design is professional
and the content is well organized. At present it is both in Chinese and English
versions.
Email: jinhe@biotaxu.com ; zishan@biotaxu.com
Qualifications:
SC has obtained ISO 9001 and High-Tech Enterprises
Certification
No significant changes were found during our checks with local AIC.
MAIN SHAREHOLDERS:
Name %
of Shareholding
Zhang Aiping 5
Zhang Weizhong 95
l
Legal representative and chairman:
Mr. Zhang Weizhong is currently
responsible for the overall management of SC.
Working Experience(s):
At present Working
in SC as legal representative and chairman
l
Supervisor
Zhang Aiping
SC is mainly
engaged in researching, developing, manufacturing and selling Anti-cancer APIs and
intermediates.
SC’s products
mainly include Paclitaxel, Docetaxel Anhydrous (Trihydrous),
Cabazitaxel, Irinotecan HCl Trihydrate, Etoposide, Palonosetron Hydrochloride,
10 DAB III, Podophyllotoxin etc. These products are mainly used for Anti-cancer drugs.
SC sources its materials 40%
from domestic market, and 60% from overseas market. SC sells 20% of its
products in domestic market, and 80% to overseas market, mainly USA and Europe
markets.
The buying terms of SC include Check, T/T, L/C and Credit of
30-60 days. The payment terms of SC include Check, T/T, L/C and Credit of 30-60
days.
Note: SC’s management declined to release its major suppliers and
customers.
According to SC’s website:
Yixing Jinhe Bio-Tech Co., Ltd.
Overall payment appraisal :
( ) Excellent (
) Good (X) Average (
) Fair ( ) Poor
( ) Not yet determined
The appraisal serves as a reference to reveal SC's payments habits and ability
to pay. It is based on the 3 weighed
factors: Trade payment experience
(through current enquiry with SC's suppliers), our delinquent payment records
and our debt collection record concerning SC.
Trade payment experience : SC did not provide any name of trade/service
suppliers and we have no other sources to conduct the enquiry at present.
Delinquent
payment record : None in our database.
Debt collection record :No overdue amount owed by SC was placed to us for
collection within the last 6 years.
SC’s management
declined to release its bank details.
SC’s financial
reports were not found during our checks with the local Administration for
Industry and Commerce.
SC’s management
declined to release any financial information.
SC is considered medium-sized in its line with a development history of
10 years. Credit dealings with SC should be confined into small amount at
present.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.52.48 |
|
|
1 |
Rs.84.65 |
|
Euro |
1 |
Rs.69.25 |
INFORMATION DETAILS
|
Report Prepared
by : |
PDT |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit transaction.
It has above average (strong) capability for payment of interest and
principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with full
security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess SC’s credit risk and
to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.